SEARCH

SEARCH BY CITATION

References

  • 1
    Requirements for thromboplastins and plasma used to control oral anticoagulant therapy (Requirements for Biological Substances no. 30, revised 1982). In: WHO Expert Committee on Biological Standardization. Thirty-Third report. Annex 3, WHO Technical Report Series, no. 687. Geneva: World Health Organization, 1983.
  • 2
    Quick AJ. The prothrombin in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 734.
  • 3
    Campbell E, Link KP. Studies on the haemorrhagic sweet clover disease. J Biol Chem 1941; 138: 2133.
  • 4
    Butt HR, Allen AV, Bollman JR. A preparation from spoiled sweet clover which prolongs coagulation time and prothrombin time of blood. Proc Staff Meet Mayo Clin 1941; 16: 38895.
  • 5
    Poller L. The effect of the use of different tissue extracts on one-stage prothrombin times. Acta Haematol 1964; 32: 2928.
  • 6
    Wright IS, Beck DF, Marple CD. Myocardial infarction and its treatment with anticoagulants. Summary of findings in 1,031 cases. Lancet 1954; 1: 925.
  • 7
    Poller L, Samama M. Laboratory monitoring of oral anticoagulant therapy. Clin Lab Med 1994; 14: 81323.
  • 8
    Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international survey. Br J Haematol 1982; 51: 47985.
  • 9
    Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AGG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. New Engl J Med 1982; 27: 167681.
  • 10
    Poller L. Standardization of anticoagulant treatment: the Manchester Regional Thromboplastin Scheme. Br Med J 1964; ii: 5656.
  • 11
    Poller L. The British comparative thromboplastin: the use of the national thromboplastin reagent for uniformity of laboratory control of oral anticoagulants and expression of results. ACP Broadsheet 1970; 71: 16.
  • 12
    International Committee on Thrombosis Haemostasis/International Committee for Standardization in Haematology. Prothrombin time standardisation: report of the expert panel on oral anticoagulant control. Thromb Haemost 1979; 42: 1073114.
  • 13
    Miale JB, La Fond D. 1963 Prothrombin time test survey. College of American Pathologists, Standards Committee, Subcommittee on Coagulation. Am J Clin Pathol 1967; 47: 4059.
  • 14
    Biggs R, Denson KWE. Standardisation of the one-stage prothrombin time for the control of anticoagulant therapy. Br Med J 1967; 1: 846.
  • 15
    Kirkwood TBL. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49: 23844.
  • 16
    WHO Expert Committee on Biological Standardization. Twenty-Eighth Report. WHO Technical Report Series, no. 610. Geneva: World Health Organization, 1977.
  • 17
    Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985; 54: 1556.
  • 18
    Hermans J, Van Den Besselaar AMHP, Loeliger EA, Van Der Velde EA. A collaborative calibration study of reference materials for thromboplastins. Thromb Haemost 1983; 50: 7127.
  • 19
    Van Den Besselaar AMHP, Gralnick HR, Lewis SM. Thromboplastin Calibration and Oral Anticoagulant Control. The Hague: Martinus-Nijhoff, 1984.
  • 20
    Van Der Velde EA. P25-39 in Orthogonal Regression Equation, in Thromboplastin Calibration and Oral Anticoagulant Control. The Hague: Martinus-Nijhoff, 1984.
  • 21
    Loeliger EA, Poller L, Samama M, Thomson JM, Van Den Besselaar AMHP, Vermylen J, Verstraete M. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 1985; 54: 5157.
  • 22
    Hirsh J, Deykin D, Poller L. ‘Therapeutic range’ for oral anticoagulant therapy. Chest 1986; 89 (Suppl.): 11S15S.
  • 23
    Hirsh J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1992; 102 (Suppl.): 312S26S.
  • 24
    Hirsh J, Dalen JE, Deykin D, Poller L, Bussey HI. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (Suppl.): 231S46S.
  • 25
    Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119 (Suppl.): 8S21S.
  • 26
    Fairweather RB, Ansell J, Van Den Besselaar AMHP, Brandt JT, Bussey HI, Poller L, Triplett DA, White RH. Laboratory monitoring of oral anticoagulant therapy: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 1998; 122: 76881.
  • 27
    Loeliger EA, Lewis SM. Progress in laboratory control of oral anticoagulants. Lancet 1982; 2: 31820.
  • 28
    Poller L. Laboratory control of anticoagulant therapy. Sem Thromb Hemost 1986; 12: 139.
  • 29
    Hirsh J, Poller L. The International Normalized Ratio. A guide to understanding and correcting its problems. Arch Intern Med 1994; 154: 282.
  • 30
    Poller L, Hirsh J. Practical dosing considerations with warfarin and optimal therapeutic range. In: PollerL, HirshJ, eds. Oral Anticoagulants. London: Arnold, 1996: 16891.
  • 31
    Finney DJ. Calibration of thromboplastins. Proc R Soc Lond B Biol Sci 1995; 262: 715.
  • 32
    Van Den Besselaar AMHP, Bertina RM. Multicenter study of thromboplastin calibration precision: influence of reagent species, composition, and International Sensitivity Index (ISI). Thromb Haemost 1993; 69: 3540.
  • 33
    Poller L, Taberner DA, Thomson JM, Morris J, Mibashan RS, Shinton NK. Effect of the choice of WHO international reference preparation for thromboplastin on international normalized ratios. J Clin Pathol 1993; 46: 646.
  • 34
    Tripodi A, Chantarangkul V, Braga M, Poller L, Ten Cate JW, Van Den Besselaar AMHP, Mannucci PM. Results of a multicenter study assessing the status of standardization of a recombinant thromboplastin for the control of oral anticoagulant therapy. Thromb Haemost 1994; 72: 2617.
  • 35
    Tripodi A, Chantarangkul V, Negri B, Clerici M, Mannucci PM. International Collaborative Study for the Calibration of a Proposed Reference Preparation for Thromboplastin, Human Recombinant, Plain. Thromb Haemost 1998; 79: 43943.
  • 36
    Hirsh J, Poller L. Laboratory monitoring of anticoagulants. In: PollerL, HirshJ, eds. Oral Anticoagulants. London: Arnold, 1996: 4964.
  • 37
    Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy. In: WHO Expert Committee on Biological Standardization. Forty-Eighth Report. Annex 3. WHO Technical Report Series, no. 889. Geneva: World Health Organization, 1999: 6493.
  • 38
    Tripodi A, Poller L, Van Den Besselaar AMHP. A proposed scheme for calibration of international reference preparations of thromboplastin for the prothrombin time. Thromb Haemost 1995; 74: 13689.
  • 39
    Van Den Besselaar AMHP. Multicenter Study of Replacement of the International Reference Preparation for Thromboplastin, Rabbit, Plain. Thromb Haemost 1993; 70: 7949.
  • 40
    Van Den Besselaar AMHP. Accelerated degradation test of lyophilised recombinant tissue factor liposome preparations. Thromb Haemost 1995; 73: 3927.
  • 41
    Thomson JM, Tomenson JA, Poller L. The Calibration of the Second Primary International Reference Preparation for Thromboplastin (Thromboplastin, Human, Plain, Coded BCT/253). Thromb Haemost 1984; 52: 33642.
  • 42
    Van Den Besselaar AMHP. Multicenter calibration of the third BCR reference material for thromboplastin, rabbit, plain, coded CRM 149S. Long-term stability of previous BCR reference materials. Thomb Haemost 1995; 74: 14657.
  • 43
    Van Den Besselaar AMHP. Heat stability of two candidate international reference preparations for recombinant human tissue factor. Thomb Haemost 1997; 78: 8524.
  • 44
    Poller L, Pulford J, Stevenson KJ, Cooper P, Gamble G, Thomson JM. Long-term stability studies on the WHO IRP for thromboplastin (Human Plain BCT/253). Thromb Haemost 1994; 72: 6824.
  • 45
    Poller L. The Prothrombin Time. WHO/LAB/98.3. 1998.
  • 46
    Poller L, Keown M, Chauhan N, Van Den Besselaar AMHP, Tripodi A, Shiach C, Jespersen J. A multicentre calibration study of WHO International Reference Preparations for thromboplastin, rabbit (RBT/90) and human (rTF/95). (To be published.)
  • 47
    Tomenson JA. A statistician's independent evaluation. In: Van Den BesselaarAMHP, LewisSM, GralnickHR, eds. Thromboplastin Calibration and Oral Anticoagulant Control. Boston: Martinus-Nijhoff, 1984: 87108.
  • 48
    Poller L, Van Den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. Correction for lack of coincidence of normal and abnormal calibration slopes in ISI determination. Thromb Haemost 1999; 81: 9359.
  • 49
    Poller L, Thomson JM, Taberner DA, Clarke DK. The correction of coagulometer effects on international normalized ratios: a multicentre evaluation. Br J Haematol 1994; 86: 1127.
  • 50
    Poller L, Thomson JM, Taberner DA. Effect of automation on the prothrombin time test in NEQAS surveys. J Clin Pathol 1989; 42: 97100.
  • 51
    Poller L, Barrowcliffe TW, Van Den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. The European Concerted Action on Anticoagulation (ECAA) evaluation of a set of lyophilized normal plasmas to establish the normal prothrombin time for coagulometer systems. Thromb Haemost 1998; 79: 1228.
  • 52
    D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Macagni A, Manotti C. Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time. Am J Clin Pathol 1989; 92: 3218.
  • 53
    Poggio M, Van Den Besselaar AMHP, Van Der Velde EA, Bertina RM. The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost 1989; 62: 86874.
  • 54
    Ray MJ, Smith IR. The dependence of the international sensitivity index on the coagulometer used to perform the prothrombin time. Thromb Haemost 1990; 63: 4249.
  • 55
    Clarke K, Taberner DA, Thomson JM, Morris JA, Poller L. Assessment of value of calibrated lyophilised plasmas to determine International Sensitivity Index for coagulometers. J Clin Pathol 1992; 45: 5860.
  • 56
    Chantarangkul V, Tripodi A, Mannucci PM. The effect of instrumentation on thromboplastin calibration. Thromb Haemost 1992; 67: 5889.
  • 57
    Van Rijn JLML, Schmidt Nico A, Rutten W. Correction of instrument and reagent based differences in determination of International Normalised Ratio. Clin Chem 1989; 355: 8403.
  • 58
    Poller L, Van Den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. The European Concerted Action on Anticoagulation (ECAA): field studies of coagulometer effects on the ISI of ECAA thromboplastins. Thromb Haemost 1998; 80: 61523.
  • 59
    Poller L, Van Den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. A comparison of artificially-depleted, lyophilised coumarin and fresh coumarin plasmas in thromboplastin calibration. Br J Haematol 1998; 101: 4627.
  • 60
    Poller L. INR and the therapeutic range. Biol Clin Hematologica 1987; 9: 20313.
  • 61
    Taberner DA, Poller L, Thomson JM, Darby KV. Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR). J Clin Pathol 1989; 42: 926.
  • 62
    Van Den Besselaar AMHP. Precision and accuracy of the International Normalized Ratio in oral anticoagulant control. Haemostasis 1996; 26 (Suppl. 4): 24865.
  • 63
    McKernan A, Thomson JM, Poller L. The reliability of International Normalised Ratios: an international multicentre study. Clin Lab Haematol 1988; 10: 6371.
  • 64
    Miale JB, La Fond DJ. Prothrombin time standardisation. Am J Clin Pathol 1969; 52: 15460.
  • 65
    Miale JB, Kent JW. Performance characteristics of reference thromboplastins. Am J Clin Pathol 1973; 40: 4537.
  • 66
    Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K. The value of plasma calibrants in correcting coagulometer effects on International Normalized Ratios. An International Multicenter Study. Am J Clin Pathol 1995; 103: 35865.
  • 67
    Tripodi A, Chantarangkul V, Manotti C, Poggi M, Braga M, Akkawat B, Bucciarelli P, Mannucci PM. A simplified procedure for thromboplastin calibration—the usefulness of lyophilized plasmas assessed in a collaborative study. Thromb Haemost 1996; 75: 30912.
  • 68
    Kitchen S, Jennings I, Woods TAL, Preston FE. Local calibration of International Normalised Ratio improves between laboratory agreement: results from the UK National External Quality Assessment Scheme. Thromb Haemost 1999; 81: 605.
  • 69
    Poller L, Barrowcliffe TW, Van Den Besselaar AMHP, Jespersen J, Tripedi A, Houghton D. European Concerted Action on Anticoagulation (ECAA): clinical and laboratory studies. Hematology 1998; 3: 32132.
  • 70
    Van Den Besselaar AMHP, Witteveen E, Schaefer-van Mansfeld H, Van Rijn C, Van Der Meer FJM. Effect of plasma pooling on the International Sensitivity Index of prothrombin time systems. Blood Coagul Fibrinolysis 1998; 9: 64551.
  • 71
    Barrowcliffe TW, Van Den Besselaar AMHP, Houbouyan-Réveillard, LL, Jespersen J , Johnston M, Poller L, Tripodi A. Guidelines on preparation, certification and use of certified plasmas for ISI calibration and INR determination. On behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the ISTH. (To be published.)
  • 72
    Poller L, Keown M, Shepherd SA, Shiach CR, Tabeart S. The effects of freeze drying and freeze drying additives on the prothrombin time and the international sensitivity index. J Clin Pathol 1999; 52: 7448.
  • 73
    Adcock DM, Johnston M. Evaluation of frozen plasma calibrants for enhanced standardization of the International Normalised Ratio (INR): a multi-center study. Thromb Haemost 2002; 87: 749.
  • 74
    Poller L, Barrowcliffe TW, Van Den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. Minimum lyophilized plasma requirement for ISI calibration. Am J Clin Pathol 1998; 109: 196204.
  • 75
    Chantarangkul V, Tripodi A, Cesana BM, Mannucci PM. Calibration of local systems with lyophilized calibrant plasmas improves the interlaboratory variability of the INR in the Italian External Quality Assessment Scheme. Thromb Haemost 1999; 82: 16216.
  • 76
    Poller L, Keown M, Chauhan N, Van Den Besselaar AMHP, Tripodi A, Shiach C, Jespersen J. Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods. Br Med J 2003; 327: 304.
  • 77
    Poller L, Keown M, Chauhan N, Van Den Besselaar AMHP, Tripodi A, Shiach C, Jespersen J. Quality assessment of the CoaguChek and TAS PT-NC whole blood prothrombin time monitors. Clin Chem 2004; 50: 53744.
  • 78
    Houbouyan LL, Goguel AF. Long-term French experience in INR standardization by a procedure using plasma calibrants. Am J Clin Pathol 1997; 108: 839.
  • 79
    Van Den Besselaar AMHP. Comparison of lyophilized plasmas with fresh plasmas for calibration of thromboplastin reagents in oral anticoagulant control. Br J Haematol 1996; 93: 43744.
  • 80
    Stevenson KJ, Craig S, Dufty JMK, Taberner DA. System ISI calibration: a universally applicable scheme is possible only when coumarin plasma calibrants are used. Br J Haematol 1997; 96: 43541.
  • 81
    Poller L, Van Den Besselaar AMHP, Jespersen J, Tripodi A, Houghton D. A comparison of linear and orthogonal regression analysis for local INR determination in ECAA coagulometers studies. Br J Haematol 1998; 102: 9107.
  • 82
    Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 142534.
  • 83
    Kearon MB, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 6319.
  • 84
    Duxbury BMcD. The therapeutic control of anticoagulant therapy. Br Med J 1982; 284: 5925.
  • 85
    Rosendaal FR, Cannegieter SC, Van Der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 2369.
  • 86
    Cannegieter SC, Rosendaal FR, Wintzen AR, Van Der Meer FJM. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 117.
  • 87
    Wilson R, James AH. Computer assisted management of warfarin treatment. Br Med J 1984; 289: 4224.
  • 88
    Ryan PJ, Gilbert M, Rose PE. Computer control of anticoagulant dose for therapeutic management. Br Med J 1989; 299: 12079.
  • 89
    Weston Smith SG, Savidge GF. Computer control of anticoagulant dose. Br Med J 1989; 299: 152930.
  • 90
    Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol 1993; 46: 299303.
  • 91
    Ageno W, Turpie AGG. A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. J Thromb Thrombolysis 1998; 5 (Suppl. 1): S69.
  • 92
    Poller L, Shiach CR, MacCallum PK, Johansen AM, Münster AM, Magalhães A, Jespersen J. Multicentre randomised study of computerised anticoagulant dosage. Lancet 1998; 352: 15059.
  • 93
    Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica 2001; 86: 106070.
  • 94
    Leaning KE, Ansell JE. Advances in the monitoring of oral anticoagulation: point-of-care testing, patient self-monitoring, and patient self-management. J Thromb Thrombolysis 1996; 3: 37783.
  • 95
    Ansell JE, Hughes R. Evolving models of warfarin management. Am Heart J 1996; 132: 1095100.
  • 96
    Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. Chest 2001; 119: 22S38S.
  • 97
    Tripodi A, Arbini AA, Chantarangkul V, Bettega D, Mannucci PM. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the International Normalized Ratio? Thromb Haemost 1993; 70: 9214.
  • 98
    Turpie AGG, Gunstensen J, Hirsh J. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1: 12425.
  • 99
    Saour JN, Sieck JO, Mamo LAR. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990; 322: 42832.
  • 100
    Altman R, Rouvier J, Gurfinkel E. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991; 101: 42731.
  • 101
    The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 23341.
  • 102
    British Society for Haematology 1990 Guidelines on oral anticoagulation, 2nd edn. J Clin Pathol 1990; 43: 17783.
  • 103
    Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 16918.